Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

NCT05704933 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

1

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma
Metastasis to Brain

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: Nivolumab + Relatlimab
PROCEDURE: Standard of Care Craniotomy

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]